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Activating mutations within the epidermal growth factor (EGFR) tyrosine kinase domain identify non-small cell lung cancer patients
with improved clinical response to tyrosine kinase inhibitor therapy. Recently, we identified two EGFR mutations in a cohort of 25
salivary gland carcinomas (SGCs) by screening the tumour samples for the both most common hotspot mutations in exons 19 and 21
by allele-specific PCR. Here, we present a comprehensive sequencing analysis of the entire critical EGFR tyrosine kinase domain in 65
SGC of the main histopathological types. We found EGFR mutations in the tyrosine kinase domain to be a rare event in SGCs. No
additional mutations other than the two known exon 19 deletions (c.2235_2249del15) in a mucoepidermoid carcinoma and an
adenoid cystic carcinoma have been detected. Other putative predictive markers for EGFR-targeted therapy in SGCs might be
relevant and should be investigated.
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Malignant salivary gland neoplasms account for o0.5% of all
malignancies and approximately 3–5% of all head-and-neck
cancers (Milano et al, 2007). Salivary gland carcinomas (SGCs)
represent a histopathologically heterogeneous group with different
biological behaviour and clinical outcome. The main histopatho-
logic types are (1) mucoepidermoid carcinoma that represents
29–34% of malignant tumours; (2) adenoid cystic carcinoma
(ACC; 20%); (3) adenocarcinoma including acinic cell carcinoma;
and (4) salivary duct carcinoma (Milano et al, 2007). Progress in
understanding the cell biology of SGCs and detecting vulnerable
molecular pathways may lead to the development of new targeted
therapy options. Epidermal growth factor (EGFR; also known as
ErbB1) is considered a possible key pathway for therapeutic
molecules. Overexpression of EGFR has been shown in
both salivary ACC and non-ACC (Agulnik et al, 2007; Ettl
et al, 2008), and these findings have provided the motivation
for trials with EGFR inhibitor-based therapies. Anti-EGFR agents
include (1) monoclonal antibodies (cetuximab or erbitux, panitu-
mumab), which block the binding of natural EGFR ligands, such as
EGF or TGF-a, resulting in inhibition of downstream signal
transduction pathways and (2) small molecule tyrosine kinase
inhibitors (TKIs), which act by binding the ATP pocket within the
kinase domain of the EGFR and impairing its catalytic activity
(gefitinib, erlotinib and lapatinib). Cetuximab (erbitux) has been
tested in two phase II studies in patients with recurrent and/or
metastatic SGCs including mainly ACC, a cancer with generally
poor outcome. In 50% of patients, clinical benefit (i.e., response or
stable disease for 6 months) could be achieved (Milano et al, 2007;
Locati et al, 2008). Gefitinib was associated with a 53% stable
disease rate (10/19) in ACC, but had no effects in patients with
salivary duct tumours and mucoepidermoid cancer (Glisson et al,
2005). Lapatinib, inhibiting ErbB1 and ErbB2 tyrosine kinases, was
studied in a phase II trial and stabilized disease for greater than 6
months in 47% of ACC patients (Agulnik et al, 2007).
Earlier studies (Lynch et al, 2004; Paez et al, 2004; Eberhard
et al, 2005; Riely et al, 2006a) had identified a subset of lung cancer
patients with rapid and durable clinical responses to EGFR TKIs
and found an underlying association between activating mutations
in the EGFR tyrosine kinase domain and therapy response. Since
then, four validated drug-sensitising mutations and three kinase
domain mutations associated with drug resistance have been
reported (Riely et al, 2006b). As with lung adenocarcinomas,
mutations in the EGFR tyrosine kinase domain may be associated
with clinical efficacy of EGFR inhibitors in the treatment of SGCs.
Recently, we identified a mucoepidermoid carcinoma and an ACC
with a TKI-sensitising EGFR exon 19 deletion mutation by
screening EGFR exons 19 and 21 for the two most common
hotspot mutations by an allele-specific PCR test (Dahse and
Kosmehl, 2008).
The aim of this study was to sequence the entire critical EGFR
tyrosine kinase domain and to determine how frequently
drug-sensitising and drug-resistant EGFR mutations might occur
in a large cohort of SGCs of the main histopathological types.
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Surgically removed formalin-fixed tumour samples were obtained
from 65 patients (35 males and 30 females with a median age at
diagnosis of 55 years) treated with the histopathological diagnosis
of an SGC according to the WHO classification (Barnes et al, 2005).
All patients received surgery and in selected cases of postoperative
radiation therapy. Epidermal growth factor receptor-targeted
therapy was not applied. The study cohort consisted of ACC
(n¼25), mucoepidermoid carcinoma (n¼10), myoepithelial
carcinoma (n¼8), acinic cell carcinoma (n¼12) and adenocarci-
noma ex pleomorphic adenoma (n¼10).
Deoxyribonucleic acid was isolated from microdissected tumour
areas using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden,
Germany).
Epidermal growth factor exons 18, 19, 20 and 21 were amplified
by nested PCR using primers described previously (Eberhard et al,
2005). Polymerase chain reaction products were purified with the
QIAquick PCR Purification Kit (Qiagen GmbH). Genomic
sequencing was performed using fluorescent dye-terminator
chemistry and the primer M13F: 50-TGTAAAACGACGGCCAGT-30
(MWG Biotech, Martinsried, Germany). The reported mutations
were scored as reproducible, having been identified in two
independent PCR amplifications and by M13 sequencing in both
directions (M13R: 50-CAGGAAACAGCTATGACC-30).
The numbering of the EGFR nucleotide and amino acid
positions was according RefSeq sequences NM 005228.3 and NP
005219.2, respectively.
This study was conducted in accordance with the principles of
the Declaration of Helsinki, as adopted by the 29th World Medical
Assembly, Helsinki, Finland.
RESULTS
Sequencing analysis of exons 18–21 of the EGFR tyrosine kinase
domain in 65 SGCs revealed two cases (3.1, 95% exact confidence
limit: 0.5–1.2) with a heterozygous exon 19 deletion mutation. The
two exon 19 E746_A750 deletions (both of them were variant
c.2235_2249del15) were identified in a mucoepidermoid carcinoma
of the left parotid gland grade 2 (54-year-old female patient,
smoker), and in an ACC of solid type of the right parotid gland
(69-year-old male patient, non-smoker). The female patient with
the mucoepidermoid carcinoma was treated with surgery and
postoperative radiation, the male patient with ACC by surgical
tumour resection alone. Both patients had a favourable course of
their cancer disease with no manifestation of recurrences (follow-
up time 24 months).
In exon 20, an SNP c.2607 G4A (p.Q787Q) was detected in
29 out of 65 tumour samples (44.6%, 95% exact confidence limit:
32.5–57.4).
DISCUSSION
Somatic mutations in the EGFR kinase domain are found in a
subset of lung adenocarcinomas and are associated with sensitivity
to TKI (point mutations G719A/C in exon 18, L858R and L861Q in
exon 21 and in-frame deletions at position 745 of exon 19). Three
kinase domain mutations are associated with drug resistance:
D761Y in exon 19, T790M in exon 20 and an exon 20 insertion
(D770N771insNPG). The exon 19 deletions and L858R in exon 21
represent 85–90% of EGFR mutations in non-small cell lung
cancer. In two recent trials in advanced non-small cell lung cancer,
therapy with gefitinib administered in a genotype-directed fashion
to patients harbouring EGFR mutations resulted in very favourable
clinical outcomes with good tolerance (Sequist et al, 2008; Tamura
et al, 2008).
Given the comparable embryonal tissue origin between lung
adenocarcinoma and SGCs and the potential for genotype-directed
trials of EGFR inhibitors, we undertook a comprehensive
mutational analysis of EGFR in SGCs. We found EGFR mutations
in the tyrosine kinase domain to be a rare event in SGCs
of Caucasian origin. Whereas approximately 10–30% of lung
carcinoma contain EGFR mutations (Mitsudomi and Yatabe,
2007), they seem to be seldom acquired in the cancers of other
organs (EGFR mutation database:http://www.cityofhope.org/cmdl/
egfr%5Fdb/).
Both of the mutations detected in our cohort were found in
histopathological types (mucoepidermoid carcinoma and ACC),
which also occur in the lung. In a recently published study, in two
out of five (40%) of mucoepidermoid carcinoma of lung (which
originate from minor salivary glands of the tracheobrochial tree),
the L858R mutation was detected and all five patients well
responded to TKI therapy independent of the mutation status
(Han et al, 2008). In contrast, in another study with 24 cases
of adenoid cystic and mucoepidermoid salivary gland-type
lung carcinomas, EGFR protein expression was found in 91%,
but no mutation was detected in exons 18–21 of the EGFR
gene (Macarenco et al, 2008). In head-and-neck cancers,
in which about 10% of cases showed responses to gefitinib,
no mutations were noted in a US study, but 7% of tumours of
Asian origin were found to harbour such mutations (Cohen et al,
2005; Lee et al, 2005).
In conclusion, drug-sensitising EGFR mutations are rather rare
in SGCs and seem to be mainly found in a few mucoepidermoid
and ACC. Taking into consideration the encouraging relative high
number of responding SGC patients (particularly ACC patients
with poor prognosis) who achieved stable disease after cetuximab
treatment in the phase II trials and the apparently low incidence of
drug-sensitising EGFR mutations, it would appear that also other
biological factors than EGFR tyrosine kinase mutations might
influence the therapy response. The underlying mechanisms of
response to targeted therapies are complex and still not fully
elucidated. Investigating those mechanisms and the mutation
status of proteins in the cascade downstream of EGFR might
identify further predictive markers for EGFR-targeted therapy in
SGCs and would allow the selection of patients for a successful
treatment.
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